BE Study of Naftifine HCL

NCT02633813 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

693

Enrollment

INDUSTRY

Sponsor class

Conditions

Tinea Pedis

Interventions

DRUG: Naftifine hydrochloride 2%
DRUG: Placebo
DRUG: Naftin® 2% (Naftifine hydrochloride 2%)

Sponsor

Genzum Life Sciences